Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial
RCT (n=260) found a superior median progression-free survival in the trametinib group vs standard-of-care (13.0 vs 7.2 months; HR for progression or death 0.48, 95% CI 0.36–0.64). Authors suggest trametinib could represent a new standard-of-care option for these patients.
Source:
The Lancet
SPS commentary:
Commentary discusses the evolution of cancer therapeutics. It notes that up to 10% of serous ovarian cancer cases are classified as low-grade and are poorly responsive to chemotherapy, have high oestrogen and progesterone receptor expression, and, in 30–60% of cases, contain activating mutations in the MAPK pathway which trametinib actively targets.